Fampridine Acorda Therapeutics

Current Opinion in Investigational Drugs

Volumn 1, Issue 3, 2000, Pages 375-379

  Darlington, C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; BENZODIAZEPINE DERIVATIVE; NORADRENALIN; SEROTONIN;

CLINICAL TRIAL; CONFUSION; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SYNTHESIS; GRAND MAL SEIZURE; HUMAN; MULTIPLE SCLEROSIS; NERVE CONDUCTION; PARESTHESIA; REVIEW; SPINAL CORD INJURY; STRUCTURE ACTIVITY RELATION; VERTIGO;

4-AMINOPYRIDINE; ANIMALS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; MULTIPLE SCLEROSIS; NOOTROPIC AGENTS; SPINAL CORD INJURIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033677618     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Elan's fampridine nears phase III
2. Pharmacokinetic-pharmacodynamic (PK-PD) model of fampridine in Sprague-Dawley rats
3. Dual effect of 4-aminopyridine on low threshold potassium channels of neuronal membrane
4. Effect of 4-aminopyridine in acute spinal cord injury
5. 4-aminopy-ridine (4-AP) antagonizes saxitoxin (STX) induced lethality
6. Drug development pipeline: Naproxen sodium, natalizumab, A-beta-I-196, fampridine, tizanidine and AN-072
7. Elan announces first quarter 1997 results
8. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis
9. The effects of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, cross-over study
10. The effects of 4-aminopyridine in multiple sclerosis patients. Results of a randomized, placebo-controlled, double-blind, concentration-controlled crossover trial
11. Acorda raises $20M; will bring some R and D in-house
12. Mechanism of the contractile effect of 4-aminopyridine in porcine coronary artery
13. Slow sodium-dependent potential oscillations contribute to ectopic firing in mammalian demyelinated axons
14. Atypical presentation of 4-aminopyridine overdose
15. The effects of anticonvulsants on 4-aminopyridine-induced bursting: In vitro studies on rat peripheral nerve and dorsal roots
16. The treatment of multiple sclerosis: Current and future
17. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury
18. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentation-controlled, crossover trial
19. The current status of studies of aminopyridines in patients with multiple sclerosis
20. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis
21. 4-Aminopyridine in patients with multiple sclerosis: Dosage and serum level related to effecacy and safety
22. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: Three cases
23. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury
24. Drug development pipeline - Acorda Therapeutics
25. Acorda Therapeutics to begin late-stage phase II clinical trial of fampridine-sr in spinal cord injury
26. Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury
27. Intravenous infusion of 4-AP in chronic spinal cord injured subjects
28. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial
29. FDA to facilitate 4-AP compassionate use INDs for MS, Axelrad says
30. Production site transfer successful approaches to overcoming technical, regulatory and compliance challenges, San Francisco, CA, USA
31. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension
32. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis
33. Drug development pipeline - Fampridine
34. Burrill and Co 1999 quarterly press releases - 4th quarter report
35. Drug development pipeline - Fampridine